TICKERNERD
Menu
NKTRNKTRHealthcare · Biotechnology

NKTR Stock Forecast: Nektar Therapeutics Price Predictions for 2026-2027

Last close, 21 Aug 2026
$74
−0.68% on the day

The 12 Wall Street analysts covering Nektar Therapeutics hold a median 12-month price target of $151 — +103.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$2.5B
Ticker Nerd rank
52 / 100
Median analyst target
$151
Analysts covering
12
Total return, dividends reinvested
1W
+1.4%
1M
+7.8%
YTD
+75.1%
1Y
+164.4%
From 52W high
−26.2%
From 52W low
+173.8%
$27
$100
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NKTR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nektar Therapeutics on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
83
Revisions
75
Quality
72
Growth
54
Value
51
Issuance
49
Size
34
Volatility
17
Accruals
11

Momentum (83): The shares have been drifting up relative to others.

Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NKTR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NKTR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200Oct 25Jan 26Apr 26Jul 26NKTRHigh $192Median $151Low $65

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
10 Buy2 Hold0 Sell
Low $65Median $151High $192

The green dot is the last close — the median target sits +103.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 July 2026Canaccord GenuityInitiatesBuy$153
11 May 2026WedbushMaintainsNeutral—
11 May 2026WedbushMaintainsNeutral$95 → $80
8 May 2026Piper SandlerMaintainsOverweight—
8 May 2026Piper SandlerMaintainsOverweight$105 → $192
21 Apr 2026CitigroupMaintainsBuy—
21 Apr 2026WedbushMaintainsNeutral—
20 Apr 2026BTIGMaintainsBuy—
20 Apr 2026HC Wainwright & Co.MaintainsBuy—
24 Mar 2026WedbushInitiatesNeutral—
17 Mar 2026TD CowenInitiatesBuy—
16 Mar 2026CitigroupMaintainsBuy—
23 Feb 2026B. Riley SecuritiesReiteratesBuy—
10 Feb 2026BTIGMaintainsBuy—
10 Feb 2026HC Wainwright & Co.MaintainsBuy—
29 Jan 2026BTIGReiteratesBuy—
16 Dec 2025BTIGMaintainsBuy—
16 Dec 2025HC Wainwright & Co.MaintainsBuy—
26 Nov 2025CitigroupInitiatesBuy—
26 Nov 2025JefferiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NKTR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NKTR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Nektar Therapeutics (NKTR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.6×

Cheaper than 92% of US stocks

Price / sales
46.3×

Cheaper than 6% of US stocks

Price / book
2.8×

Cheaper than 36% of US stocks

EV / EBITDA
−15.2×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
−9.3%

Higher than 16% of US stocks

Earnings growth (YoY)
3.8%

Higher than 40% of US stocks

Gross margin
—
Operating margin
−412.2%

Higher than 8% of US stocks

Net margin
−287.8%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−35.8%

Higher than 25% of US stocks

Return on assets
−12.5%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NKTR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NKTRNektar Therapeutics$2.5B
52
PHVSPharvaris NV$2.5B
42
NUVBNuvation Bio, Inc.$2.4B
63
RAREUltragenyx Pharmaceutical, Inc.$2.5B
49
PGENPrecigen, Inc.$2.5B
82
TRVITrevi Therapeutics, Inc.$2.5B
54
OCULOcular Therapeutix, Inc.$2.3B
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nektar Therapeutics — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NKTR news & analysis

Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming

Seeking Alpha · 14 Aug 2026positive

Seeking Alpha reaffirms a Strong Buy rating on Nektar Therapeutics, citing REZPEG's late-stage development for atopic dermatitis and alopecia areata. The Phase 3 ZENITH AD program, comprising three pivotal studies in moderate-to-severe AD subpopulations, is underway with topline data expected by mid-2028.

Why it matters — NKTR watchers would care because REZPEG's Phase 3 program is positioned as a key upcoming catalyst with a differentiated mechanism aimed at long-term disease control and safety advantages in a large global AD market.

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Zacks Investment Research · 14 Aug 2026neutral

Nektar Therapeutics reported second-quarter earnings that beat analyst estimates, though revenues fell short of expectations. Investor attention remains focused on rezpeg as late-stage studies advance in autoimmune diseases.

Why it matters — NKTR watchers would care because the mixed quarterly results combine with the late-stage progress of rezpeg, the key program driving near-term investor focus.

Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the transcript of Nektar Therapeutics' Q2 2026 earnings call, covering the company's quarterly results and management commentary. The item is the full earnings call transcript for the second quarter of 2026.

Why it matters — The transcript gives NKTR watchers direct access to management's discussion of the company's latest quarterly performance and outlook.

Nektar Therapeutics Q2 Earnings Call Highlights

MarketBeat · 14 Aug 2026positive

Nektar Therapeutics, during its Q2 earnings call, reported initiating its global Phase III ZENITH AD program for rezpegaldesleukin (REZPEG) in moderate-to-severe atopic dermatitis in July. The company also finalized plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting with the FDA.

Why it matters — Advancing REZPEG into late-stage trials for two indications signals meaningful progress in Nektar's core pipeline that NKTR watchers would track closely.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 13 Aug 2026neutral

Nektar Therapeutics reported a Q2 loss of $1.23 per share, narrower than the loss of $2.06 per share expected by the Zacks Consensus Estimate and smaller than the $2..78 per share loss a year earlier. The company missed revenue estimates for the quarter.

Why it matters — The narrower-than-expected quarterly loss may interest NKTR watchers tracking the company's financial trajectory, though the revenue miss remains a point of concern.

FAQ

Frequently asked questions about NKTR stock

What is the NKTR stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Nektar Therapeutics have a median 12-month price target of $151, with estimates ranging from $65 to $192. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NKTR stock a buy right now?

Of the 12 analysts covering Nektar Therapeutics, 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nektar Therapeutics 52 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NKTR?

As at 22 Aug 2026, Nektar Therapeutics ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).

Will NKTR stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +103.3% from the last close, and Ticker Nerd's factor model ranks Nektar Therapeutics 52 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NKTR stock forecast for 2030?

No analyst covering Nektar Therapeutics publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NKTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $192 over the next 12 months.

How has NKTR stock performed over the past year?

Nektar Therapeutics returned +164.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nektar Therapeutics do?

Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States and internationally.

What is the latest news on NKTR?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming". Seeking Alpha reaffirms a Strong Buy rating on Nektar Therapeutics, citing REZPEG's late-stage development for atopic dermatitis and alopecia areata. The Phase 3 ZENITH AD program, comprising three pivotal studies in moderate-to-severe AD subpopulations, is underway with topline data expected by mid-2028.

Company

About Nektar Therapeutics.

Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States and internationally. Its lead product candidate, rezpegaldesleukin (also known as REZPEG or NKTR-358), is a novel regulatory T cell stimulator and IL-2 pathway agonist designed to restore immune system balance in conditions such as moderate-to-severe atopic dermatitis, severe-to-very-severe alopecia areata, and Type 1 diabetes mellitus. The company is advancing rezpegaldesleukin through Phase 2b clinical trials, including the REZOLVE-AD and REZOLVE-AA studies, which evaluate subcutaneous injections for efficacy in disease control and patient outcomes. Beyond its lead asset, Nektar Therapeutics Inc. maintains a pipeline of investigational programs targeting immune pathways, such as a preclinical bivalent tumor necrosis factor receptor type II agonist, bispecific molecules NKTR-0165 and NKTR-0166, a modified hematopoietic colony stimulating factor protein NKTR-422, and NKTR-255, an IL-15 receptor agonist developed in collaboration for oncology applications to enhance anti-tumor immune responses. Founded in 1990 and headquartered in San Francisco, California, Nektar Therapeutics Inc. leverages expertise in polymer chemistry and immunology to create highly selective medicines addressing unmet needs in immunotherapy.

CEO Mr. Howard W. Robin · 63 employees · United States · https://www.nektar.com